Employers that offer health insurance to workers should brace for a surge in spending on new "specialty" medications, a University of Minnesota expert said Friday.
U pharmacy Prof. Stephen Schondelmeyer said that drug companies have a huge pipeline of promising pharmaceuticals that are scheduled to come to market in the coming years.
Medication budgets already have been stretched by the launch of expensive new treatments for hepatitis C, multiple sclerosis and other health problems, Schondelmeyer told more than 100 people gathered for a health care forum in Edina.
With more new medications coming, employers by 2023 will find they're spending more on medications than they do on care from physicians.
"I applaud the bringing of these drugs to the marketplace — I'm not saying we shouldn't treat this," Schondelmeyer said. "But we need to put into perspective the cost. … The cost structure is simply not sustainable."
The comments came during the eighth annual summit sponsored by the Minnesota Health Action Group, a coalition of more than 50 employers pushing for better value in the health care system.
For years, the group has operated a program that provides financial rewards to clinics that provide optimal care to patients with certain health conditions.
The annual summit highlights areas of concern for employers, and the cost of specialty pharmaceuticals has risen to the top of the list for many, said Carolyn Pare, the group's chief executive. The employer group is working with Schondelmeyer on a project that will give both employers tools for handling costs, while also pushing for policy changes.